+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
22 Mar 2022

Case Study : Vimpat patent expired on 17th of March, 2022 and generic entry

Posted By

It’s all happening now. Finally Vimpat (Lancosamide) patent is expired on 17th of March. And dozens of generics approved on 17th of March.

Lacosamide Tablets are available in 50 mg, 100 mg, 150 mg and 200 mg strengths. VIMPAT® was approved in the U.S. in 2008 as an add-on therapy for the treatment of partial-onset seizures in adult patients with epilepsy. VIMPAT was approved as monotherapy for adults in August 2014, and as monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures in 2017.

You can see below the generics approval status as on date (till 23rd of March, 2022).

Vimpat Generic Approval


Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests